Kinetics of lung clearance of 99mTc-DTPA in smoking patients with sarcoidosis compared to healthy smokers

Respiratory Medicine

Volumn 96, Issue 5, 2002, Pages 317-321

  Bradvik I ^a   Wollmer, P ^a   Evander, E ^a   Larusdottir H ^a   Blom Bulow B ^a   Jonson, B ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Radionuclide imaging; Sarcoidosis; Smoking; Technetium 99 m pentetate

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; METHYLPREDNISOLONE; PENTETATE TECHNETIUM TC 99M; STEROID;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG CLEARANCE; LUNG SARCOIDOSIS; LUNG SCINTISCANNING; PRIORITY JOURNAL; SPIROMETRY; THORAX RADIOGRAPHY; TIME;

EID: 0036586864     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2001.1285     Document Type: Article

References (19)

1. 99m Tc-DTPA, lung surfactant and lung injury: a review of the literature. Appl Cardiopulm Pathophys 1991; 4: 155-160.
2. Nery LE, Florencio RT, Sandoval PRM, Rodrigues RT, Alonso G, Mason GR. Additive effects of exposure to silica dust and smoking on pulmonary epithelial permeability: a radioaerosol study with technetium-99m labelled DTPA. Thorax 1993; 48: 264-268.
3. Brådvik I, Wollmer P, Evander E, Lárusdóttir H, Blom-Bülow B, Jonson B. Different kinetics of lung clearance of technetium-99m labelled diethylene triamine penta-acetic acid in patients with sarcoidosis and smokers. Eur J Nucl Med 1994; 21: 1218-1222.
4. 99m Tc-DTPA in smokers. Clin Physiol 1994; 14: 547-559.
5. 99m Tc-DTPA. Am Rev Respir Dis 1990; 141: 445-449.
6. 99m Tc-DTPA and pulmonary involvement in sarcoidosis. Am Rev Respir Dis 1986; 134: 493-497.
7. Jacobs MP, Baughman RP, Hughes J, Fernandez-Ulloa M. Radio-aerosol lung clearance in patients with active pulmonary sarcoidosis. Am Rev Respir Dis 1985; 131: 687-689.
8. 99m Tc-DTPA clearance measured by a dual head gamma camera in healthy subjects and in patients with sarcoidosis. Eur J Nucl Med 1989; 15: 71-77.
9. Eklund A. Alveolitis in sarcoidosis. Studies on markers of disease activity. Doctoral thesis. Karolinska Institute, Stockholm, Sweden, 1986.
10. Holmqvist B, Bünning P, Riordan JF. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem 1979; 95: 540-548.
11. Berglund E, Birath G, Bjure J, et al. Spirometric studies in normal subjects. I. Forced expirograms in subjects between 7 and 70 years of age. Acta Med Scand 1963; 173: 185-192.
12. Jones JG, Minty BD, Lawler P, Hulands G, Crawley JCW, Veall N. Increased alveolar permeability in cigarette smokers. Lancet 1980; 1: 66-68.
13. Mason GR, Uszler JM, Effros RM, Reid E. Rapidly reversible alterations of pulmonary epithelial permeability induced by smoking. Chest 1983; 83: 6-11.
14. Brådvik I, Wollmer P, Evander E, et al. Lung function and disease activity in sarcoidosis. Appl Cardiopulm Pathophysiol 1996; 6: 61-70.
15. Low RB, Davis GS, Bell DY, Giancola MS, Vacek PM. Lipids in bronchoalveolar lavage fluid from patients with sarcoidosis. Thorax 1987; 42: 926-932.
16. Schmekel B, Bos JAH, Kahn AR, Wohlfart B, Lachmann B, Wollmer P. Integrity of the alveolar-capillary barrier and alveolar surfactant system in smokers. Thorax 1992; 47: 603-608.
17. John J. Alveolar surfactant function in relation to lung mechanics and lung clearance mechanisms. Doctoral thesis. University of Lund, Lund, Sweden, 1995.
18. Tägil K, Evander E, Wollmer P, Palmer J, Jonson B. Efficient lung scintigraphy. Clin Physiol 2000; 20: 95-100.
19. Baudouin SV, du Bois RM. Disease activity. In: James DG, ed. Sarcoidosis and Other Granulomatous Disorders. New York: Marcel Dekker, 1994; 573-595.